Matches in Wikidata for { <http://www.wikidata.org/entity/Q37647831> ?p ?o ?g. }
- Q37647831 description "article científic" @default.
- Q37647831 description "article scientifique" @default.
- Q37647831 description "articolo scientifico" @default.
- Q37647831 description "artigo científico" @default.
- Q37647831 description "artículu científicu espublizáu en 2017" @default.
- Q37647831 description "bilimsel makale" @default.
- Q37647831 description "scientific article published on 18 February 2017" @default.
- Q37647831 description "vedecký článok" @default.
- Q37647831 description "vetenskaplig artikel" @default.
- Q37647831 description "videnskabelig artikel" @default.
- Q37647831 description "vědecký článek" @default.
- Q37647831 description "wetenschappelijk artikel" @default.
- Q37647831 description "wissenschaftlicher Artikel" @default.
- Q37647831 description "наукова стаття, опублікована в лютому 2017" @default.
- Q37647831 description "научни чланак" @default.
- Q37647831 description "مقالة علمية نشرت في 18 فبراير 2017" @default.
- Q37647831 name "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 name "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 name "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 type Item @default.
- Q37647831 label "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 label "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 label "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 prefLabel "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 prefLabel "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 prefLabel "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 P1433 Q37647831-8B41132D-662C-408A-AC81-4908AEFA5D8B @default.
- Q37647831 P1476 Q37647831-BCDFBC0B-64F2-47DC-BC19-4F6BB8227F17 @default.
- Q37647831 P2093 Q37647831-09E3D886-B5FB-466D-B5B3-991E7FD04465 @default.
- Q37647831 P2093 Q37647831-21718CFE-A56B-4112-B201-EEE4A44A4E75 @default.
- Q37647831 P2093 Q37647831-4A37BCEF-B9BF-43EE-9285-9B4ED9A30ED8 @default.
- Q37647831 P2860 Q37647831-24871E8C-8095-4E47-B3D4-18FCC381FBBB @default.
- Q37647831 P2860 Q37647831-3C1A1A0F-519F-4D9A-B3DC-68BEB880CD8A @default.
- Q37647831 P2860 Q37647831-45B29129-E8DF-44F9-91E2-C4AB1FDDEBF4 @default.
- Q37647831 P2860 Q37647831-4E4DBAD9-B17E-45A6-B8FC-5945494F0B68 @default.
- Q37647831 P2860 Q37647831-69011E89-6A2B-4020-AA2E-13EF45B50D94 @default.
- Q37647831 P2860 Q37647831-72F027C1-A3C6-472E-93EB-CB6909F642D5 @default.
- Q37647831 P2860 Q37647831-743AEF63-BB3B-4953-BEB3-65665ADB7F3F @default.
- Q37647831 P2860 Q37647831-7838EA68-EF36-4A9A-B780-531BB04F3FE8 @default.
- Q37647831 P2860 Q37647831-834AB9B4-9238-4968-BA7E-58AE50E30D67 @default.
- Q37647831 P2860 Q37647831-A49F9902-CCDB-4C7E-A4B1-ED73FC470C15 @default.
- Q37647831 P2860 Q37647831-A82CD1E5-C38F-4FF9-A871-4AAAA60869AE @default.
- Q37647831 P2860 Q37647831-B371EAAB-422A-4A30-BD88-1C2F5D0D159A @default.
- Q37647831 P2860 Q37647831-B40515BC-1A61-4FCC-8B3A-55B8FC8BCEEA @default.
- Q37647831 P2860 Q37647831-C71C5EFC-6C96-46DE-A57D-445305036D8A @default.
- Q37647831 P2860 Q37647831-C77FE96C-2E26-4B8A-B6B0-9BA54EEBE158 @default.
- Q37647831 P2860 Q37647831-D6123084-FD49-41AD-BB93-22F33E5A837F @default.
- Q37647831 P2860 Q37647831-D78B440C-34E9-46E9-ACC2-1AC146936104 @default.
- Q37647831 P2860 Q37647831-DF715A76-3094-403C-8E98-4E65736BD64D @default.
- Q37647831 P2860 Q37647831-E039536C-23AB-4FC2-B1B6-EFF1322B05BC @default.
- Q37647831 P2860 Q37647831-E35A1DDD-0BB3-44B2-9FCE-BB2D8F5FB1F7 @default.
- Q37647831 P2860 Q37647831-E3786EA4-F7B3-4ADA-AD9A-AF3B79A659DA @default.
- Q37647831 P2860 Q37647831-F0F97DA6-C11B-44E4-9AEB-155E284A6236 @default.
- Q37647831 P2860 Q37647831-F2250B3D-74B7-4373-8863-9E47858C22A8 @default.
- Q37647831 P304 Q37647831-1A1BB8B2-E352-44BB-9AAB-C8A4BE8A6300 @default.
- Q37647831 P31 Q37647831-F6163141-D645-455A-901F-E95A74DE31E0 @default.
- Q37647831 P356 Q37647831-ECB78557-4652-49AC-97F6-527A2D7B7946 @default.
- Q37647831 P433 Q37647831-21D2E19D-8E78-4CA5-ADEF-C55EC59E69B7 @default.
- Q37647831 P478 Q37647831-34D6387F-DF84-4F20-AD82-0E8E0DCCDB7A @default.
- Q37647831 P577 Q37647831-D88B1A79-9816-4D15-BC44-2F2EF18B2200 @default.
- Q37647831 P698 Q37647831-2EB54A1F-82FC-4501-849E-3F4818AD7EC2 @default.
- Q37647831 P921 Q37647831-AA428702-5BFB-4E94-A49A-F658A3948740 @default.
- Q37647831 P932 Q37647831-9F8E5635-5950-4B27-8AF5-C21B51E993B6 @default.
- Q37647831 P356 IJO.2017.02.15 @default.
- Q37647831 P698 28251088 @default.
- Q37647831 P1433 Q26841911 @default.
- Q37647831 P1476 "Characteristics of retinal vein occlusion with final vision better than 78 letters after sequential therapy with ranibizumab and triamcinolone acetate" @default.
- Q37647831 P2093 "Jia Yu" @default.
- Q37647831 P2093 "Quan Zhang" @default.
- Q37647831 P2093 "Yao-Wu Qin" @default.
- Q37647831 P2860 Q24646760 @default.
- Q37647831 P2860 Q33711660 @default.
- Q37647831 P2860 Q33828254 @default.
- Q37647831 P2860 Q33935859 @default.
- Q37647831 P2860 Q33969508 @default.
- Q37647831 P2860 Q34201060 @default.
- Q37647831 P2860 Q34338952 @default.
- Q37647831 P2860 Q37069664 @default.
- Q37647831 P2860 Q37739611 @default.
- Q37647831 P2860 Q41560304 @default.
- Q37647831 P2860 Q46173412 @default.
- Q37647831 P2860 Q46643838 @default.
- Q37647831 P2860 Q48278108 @default.
- Q37647831 P2860 Q48622596 @default.
- Q37647831 P2860 Q53058872 @default.
- Q37647831 P2860 Q53102066 @default.
- Q37647831 P2860 Q59697334 @default.
- Q37647831 P2860 Q70215917 @default.
- Q37647831 P2860 Q70379149 @default.
- Q37647831 P2860 Q73211634 @default.
- Q37647831 P2860 Q84469233 @default.
- Q37647831 P2860 Q84473325 @default.
- Q37647831 P2860 Q84558890 @default.
- Q37647831 P304 "271-276" @default.
- Q37647831 P31 Q13442814 @default.
- Q37647831 P356 "10.18240/IJO.2017.02.15" @default.
- Q37647831 P433 "2" @default.
- Q37647831 P478 "10" @default.
- Q37647831 P577 "2017-02-18T00:00:00Z" @default.
- Q37647831 P698 "28251088" @default.